CSPC Pharmaceutical Group Limited (CHJTF) Research

CSPC Pharmaceutical Group Limited operates as an investment holding company with a core focus on the research, development, manufacturing, and global commercialization of pharmaceutical products. Its extensive operations span the People's Republic of China, other Asian markets, the Americas, Europe, and various international territories. The company segments its business into Finished Drugs, Bulk Products, and Functional Food and Others. Within its diverse portfolio of finished drug products, CSPC addresses a wide array of medical conditions. Notable offerings include NBP soft capsules and injections for acute ischemic stroke, Oulaining capsules and injections designed for mild to moderate memory and mental impairment, and Enxi to manage adult idiopathic Parkinson's disease. In the oncology sector, the company provides treatments like Duomeisu for lymphomas, multiple myeloma, ovarian, and breast cancers, alongside other malignant tumors, as well as Keaili specifically for breast cancer. Additionally, Jinyouli helps prevent leucopenia and infection induced by chemotherapy. Furthermore, CSPC's product range extends to various anti-infectives, such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is targeted with Xuanning for hypertension and Encun, aimed at preventing atherosclerotic thrombosis events. For metabolic disorders, Linmeixin and Shuanglexin assist in diabetes management, while Gubang and Gubangjia treat osteoporosis in postmenopausal women. The company also offers solutions for pain and inflammation, including Qixiao for upper respiratory tract infections and Gaoshunsong, which provides relief for numerous musculoskeletal and inflammatory conditions such like different forms of arthritis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, low back pain, sprains, strains, and other soft tissue injuries. Beyond these, CSPC's therapeutic offerings feature Debixin for various ulcer conditions and Qimaite for both acute and chronic pain management. The company is also a producer of active pharmaceutical ingredients (APIs), including antibiotics, vitamin C, and caffeine, in addition to manufacturing functional food items and glucose products, and providing healthcare services. Initially incorporated in 1992 as China Pharmaceutical Group Limited, the company underwent a rebranding in March 2013 to become CSPC Pharmaceutical Group Limited. Its corporate headquarters are located in Shijiazhuang, People's Republic of China.

Open CSPC Pharmaceutical Group Limited (CHJTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.